Summit Therapeutics received a complete response letter from the FDA regarding its lung cancer drug ivonescimab. The regulator said the drug’s progression-free survival benefits were insufficient to establish a favorable benefit-risk relationship.
Source:Home – GeneOnline News · Read Original
Leave a Reply